Search STXS
Stereotaxis, Inc.
NYSE American · CIK 1289340
Last close1.18
Daily change-0.02 (-1.67%)
10 Years gain+37.21%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
STXS · STANDARD
SIC 3845 · Electromedical & Electrotherapeutic Apparatus · Fiscal year end 1231
Fundamental
34.2Momentum
100.0Acceleration
100.0Confidence
79.0Annual Revenue17
Quarterly Revenue65
Annual CFO13
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth5.6 / 25
Quality9.1 / 25
Capital Efficiency5.3 / 20
Balance Sheet13.8 / 15
Shareholder Economics0.3 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 2.7102 percentage points.
Operating leverageOperating margin improved by 24.4694 percentage points.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Heavy share dilution · HIGHDiluted share count increased 13.9712%.
Key Metrics
Revenue Growth TTM9.86%OK
Revenue CAGR 3Y4.78%OK
Gross Margin56.12%OK
Operating Margin-69.76%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y-30.29%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y13.97%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $32.38M | $17.07M | -$22.11M | -$13.69M | -$13.78M | 52.73% | -68.3% | -42.55% | n/a | 90.96M |
| 2025 FY Dec 31, 2024 | $26.92M | $14.59M | -$24.74M | -$8.50M | -$8.53M | 54.22% | -91.91% | -31.69% | n/a | 85.18M |
| 2024 FY Dec 31, 2023 | $26.77M | $14.86M | -$21.84M | -$9.14M | -$9.51M | 55.51% | -81.58% | -35.5% | n/a | 80.7M |
| 2023 FY Dec 31, 2022 | $28.15M | $18.47M | -$18.78M | -$8.42M | -$10.79M | 65.62% | -66.71% | -38.35% | n/a | 76.06M |
| 2022 FY Dec 31, 2021 | $35.02M | $23.23M | -$12.89M | -$2.95M | -$4.34M | 66.34% | -36.8% | -12.4% | n/a | 75.56M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $30.22M | sum latest 4 fiscal quarters Revenue | OK | 0001493152-26-037357, 0001493152-25-021881 |
| Revenue Growth TTM | 9.86% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001493152-26-037357, 0001493152-25-021881 |
| Revenue CAGR 3Y | 4.78% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-009881 |
| Revenue CAGR 5Y | 3.99% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001493152-26-009881 |
| Gross Profit CAGR 3Y | -2.59% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-009881 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001493152-26-037357, 0001493152-25-021881 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 56.12% | Gross Profit / Revenue | OK | 0001493152-26-037357, 0001493152-25-021881 |
| Operating Margin | -69.76% | Operating Income / Revenue | OK | 0001493152-26-037357, 0001493152-25-021881 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001493152-26-037357 |
| Current Ratio | 1.42x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.30 | Revenue / Diluted Shares | OK | 0001493152-26-037357, 0001493152-25-021881 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001493152-26-009881 |